Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

‘Heightmaxxing’ trend: Why teenagers are experimenting with a cancer drug to grow taller

‘Heightmaxxing’ trend: Why teenagers are experimenting with a cancer drug to grow taller

A social media craze dubbed 'heightmaxxing' has prompted some adolescents to experiment with erdafitinib, a prescription drug for certain cancers. However, manipulating the body's growth mechanisms without medical guidance can have grave repercussions, especially during the formative years of adolescence. Dr Monika Sharma, a Senior Consultant Endocrinology at Aakash Healthcare, elucidates that erdafitinib is designed to target urothelial cancers, including bladder cancer, in patients with certain FGFR (fibroblast growth factor receptor) genetic mutations.

"Erdafitinib functions by inhibiting FGFR proteins, which play a pivotal role in regulating cell proliferation, division, and differentiation," she explains. Dr Sharma emphasizes that the allure of this medication among teenagers is rooted in FGFR's influence on bone development and growth plates. However, she clarifies that inhibiting FGFR does not invariably result in increased stature.

The article cautions against the dangers of administering erdafitinib without medical oversight. Possible side effects include gastrointestinal issues, skin problems, oral ulcers, abnormal phosphate levels, nail disorders, joint pain, and fatigue. Additionally, there are potential eye-related complications such as central serous retinopathy, which could impair vision.

These risks are particularly alarming for teens, as their skeletal systems are still developing. Dr Sharma also highlights the concerns raised by European drug safety authorities regarding the use of erdafitinib in children, including accelerated growth and skeletal complications like epiphysiolysis of the hip, which can disrupt normal bone development.

The long-term consequences of interfering with FGFR signaling during adolescence are still unclear, and unsupervised use could delay the detection of serious side effects. The article underscores that there is no set age when individuals naturally cease growing, as the timing hinges mainly on puberty and the closure of growth plates.

Girls generally stop growing around 14 or 15, while boys might continue growing until 16 to 18. Once the growth plates fuse, no safe medication, supplement, or hormone therapy can augment one's natural height. Dr Sharma advises parents to seek the counsel of a paediatric endocrinologist if they have concerns about their teenager's height.

An assessment of growth patterns, potential hormonal issues, and bone age can help ascertain if any medical intervention is necessary. Emphasizing the importance of safety, the article reiterates that a cancer drug should never be employed as a means to grow taller.

Written by urgent.news from The Indian Express's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at indianexpress.com →

More in Health & Medicine

More from Monday 16 November →